Shimabukuro-Vornhagen A, et al. Critical care management of chimeric antigen receptor T-cell therapy recipients. Ca-Cancer J Clin. 2022;72:78–93.

Article  PubMed  Google Scholar 

Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147–67.

Article  PubMed  Google Scholar 

Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao J, et al. Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2018;93:851–8.

Article  CAS  PubMed  Google Scholar 

Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19:775–90.

Article  PubMed  PubMed Central  Google Scholar 

Deng Q, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26:1878–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrer G, Alvarez-Errico D, Esteller M. Biological and molecular factors Predicting Response to Adoptive Cell therapies in Cancer. J Natl Cancer Inst. 2022;114:930–9.

Article  PubMed  PubMed Central  Google Scholar 

Andrea AE, et al. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome hurdles in Solid Tumors Treatment. Front Immunol. 2022;13:830292.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gumber D, Wang LD, Improving. CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139–52.

Article  CAS  PubMed  Google Scholar 

Pan K, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Christofides A, et al. The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022;23:1148–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799–820.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen SZ et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Tar 8, (2023).

DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biglari A, Southgate TD, Fairbairn LJ, Gilham DE. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. Gene Ther. 2006;13:602–10.

Article  CAS  PubMed  Google Scholar 

Wang S, et al. CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine. 2022;76:103873.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauml J et al. A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. J Clin Oncol 39, (2021).

Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28:678–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science. 2022;378:853–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lecoultre M, Dutoit V, Walker PR. Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. J Immunother Cancer 8, (2020).

Morrissey MA et al. Chimeric antigen receptors that trigger phagocytosis. Elife 7, (2018).

Zhang WL, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Brit J Cancer. 2019;121:837–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13:153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu Z, et al. Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity. J Pathol. 2021;253:247–57.

Article  CAS  PubMed  Google Scholar 

Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186:1627–51.

Article  CAS  PubMed  Google Scholar 

Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23:238–57.

Article  CAS  PubMed  Google Scholar 

Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. Front Immunol 12, (2021).

Liu Q, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22:28.

Article  PubMed  PubMed Central  Google Scholar 

Su S, et al. Immune Checkpoint Inhibition overcomes ADCP-Induced Immunosuppression by macrophages. Cell. 2018;175:442–57. e423.

Article  CAS  PubMed  Google Scholar 

Villanueva MT. Macrophages get a CAR. Nat Rev Cancer. 2020;20:300.

Article  CAS  PubMed  Google Scholar 

Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for Cancer Immunotherapy. Cancer Res. 2021;81:1201–8.

Article  CAS  PubMed  Google Scholar 

Backlund C, Jalili-Firoozinezhad S, Kim B, Irvine DJ. Biomaterials-mediated Engineering of the Immune System. Annu Rev Immunol. 2023;41:153–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang M, et al. Nanocomplex-mediated in vivo programming to chimeric Antigen Receptor-M1 macrophages for Cancer Therapy. Adv Mater. 2021;33:e2103258.

Article  PubMed  Google Scholar 

Zheng CX et al. Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy. Sci Adv 9, (2023).

Chen C et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med 14, (2022).

Raimondo TM, Reed K, Shi DN, Langer R, Anderson DG. Delivering the next generation of cancer immunotherapies with RNA. Cell. 2023;186:1535–40.

Article  CAS  PubMed  Google Scholar 

Wang X, et al. Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat Commun. 2023;14:5778.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reiss KA et al. A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. J Clin Oncol 40, (2022).

Klichinsky M et al. CT-0508 is an anti-HER2 chimeric antigen receptor (CAR) macrophage with targeted anti-tumor activity that promotes a pro-inflammatory solid tumor microenvironment. Cancer Res 80, (2020).

Klichinsky M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947–953.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Annunziata CM, et al. Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. J Clin Oncol. 2020;38:3014–3014.

Article  Google Scholar 

Schepisi G et al. The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast Cancer. Cancers (Basel) 15, (2023).

Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, https://myeloidtx.com/myeloid-therapeutics-doses-first-patient-with-mt-101-in-the-imagine-phase-1-2-clinical-study/ (2023). Accessed 12 Dec 2023.

Zhang J, et al. The second generation of human iPSC-Derived CAR-Macrophages for Immune Cell therapies in Liquid and solid tumors. Blood. 2022;140:9238–9.

Article  Google Scholar 

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.

Article  CAS